A California biopharmaceutical company that claimed to be developing a cure for COVID-19 at the beginning of the pandemic faces new accusations leveled by shareholders in the Court of Chancery.

A shareholder, represented by Blake Bennett of Cooch and Taylor, says in a derivative complaint filed Tuesday that executives of San Diego-based Sorrento Therapeutics Inc. breached their duties to the company in an ill-fated attempt to raise funds by selling stock.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]